Download PDF
Thromb Haemost 1997; 78(03): 1142-1149
DOI: 10.1055/s-0038-1657701
Rapid Communication
Schattauer GmbH Stuttgart

Dissociation of Antithrombotic Effect and Bleeding Time Prolongation in Rabbits by Inhibiting Tissue Factor Function

Jacques Himber
1   F. Hoffmann-La Roche Ltd, Pharma Division, Preclinical Research Basel, Switzerland and Genentech Inc., South San Francisco, California, USA
,
Daniel Kirchhofer
1   F. Hoffmann-La Roche Ltd, Pharma Division, Preclinical Research Basel, Switzerland and Genentech Inc., South San Francisco, California, USA
,
Markus Riederer
1   F. Hoffmann-La Roche Ltd, Pharma Division, Preclinical Research Basel, Switzerland and Genentech Inc., South San Francisco, California, USA
,
Thomas B Tschopp
1   F. Hoffmann-La Roche Ltd, Pharma Division, Preclinical Research Basel, Switzerland and Genentech Inc., South San Francisco, California, USA
,
Beat Steiner
1   F. Hoffmann-La Roche Ltd, Pharma Division, Preclinical Research Basel, Switzerland and Genentech Inc., South San Francisco, California, USA
,
Sébastien P Roux
1   F. Hoffmann-La Roche Ltd, Pharma Division, Preclinical Research Basel, Switzerland and Genentech Inc., South San Francisco, California, USA
› Author Affiliations
Further Information

Publication History

Received 14 1996

Accepted after revision 23 April 1997

Publication Date:
30 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Inhibition of the tissue factor/factor Vila (TF/F. Vila) complex attenuates thrombosis in different animal models of arterial thrombosis. However, it remains unclear to what extent the antithrombotic effects are associated with changes in hemostatic functions and how this compares with inhibition of thrombin, an enzyme acting at a later stage in the coagulation cascade. The antithrombotic and the antihemostatic effects of a monoclonal anti-TF antibody (AP-1) were compared in a model of arterial thrombosis to those of a direct thrombin inhibitor (napsagatran) and heparin. In anesthetized rabbits transient arterial thrombi were induced by mechanical damage to the subendothelium of a moderately stenosed carotid artery. Recurrent formation and dis lodgement of thrombi resulted in cyclic flow variations (CFVs) which were monitored over 2 hours. Rabbits received intravenously either a placebo (control), a monoclonal anti-rabbit TF antibody (AP-1, 05 mg/kg as an i.v. bolus repeated every 15 min, a specific low molecular weight thrombin inhibitor (napsagatran, 3 fxg/kg/min) or heparin (3 and 13 fig/kg/min). The effect of the inhibitors on the hemostatic system was studied in a separate set of rabbits by measuring template bleeding times (BT) in the ear arterioles, marginal ear vein and the nail cuticle of the foreleg. AP-1 and napsagatran showed a similar antithrombotic activity (78% and 80% abolition of the CFVs, respectively), whereas either low or high dose heparin was poorly effective (43 % and 40% inhibition of CFVs, respectively). At these antithrombotic doses and even at 4-fold higher dosage, AP-1 did not significantly alter the BT, whereas napsagatran and heparin prolonged the ear vessels and cuticle BT in a dose-dependent manner. These results suggest that in contrast to direct thrombin inhibition, the blockade of the TF/F. Vila function did not result in a concomitant prolongation of the bleeding time. Thus, dissociation of antithrombotic and antihemostatic effects indicates that inhibition of the coagulation system at its initial stage represents a promising approach for the development of new anticoagulants.

 

  • References

  • 1 Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8
    PubMedGoogle Scholar
  • 2 Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-10370
    CrossrefPubMedGoogle Scholar
  • 3 Rapaport SI, Rao LVM. Initiation and regulation of tissue factor dependent blood coagulation. Arterioscler Thromb 1992; 12: 1111-1121
    CrossrefPubMedGoogle Scholar
  • 4 Wilcox JH, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-2843
    CrossrefPubMedGoogle Scholar
  • 5 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134: 1087-1097
    PubMedGoogle Scholar
  • 6 Fleck RA, Rao LVM, Rapaport SI, Varki N. Localization of human tissue factor antigen by immunostainiiig with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res 1990; 57: 765-781
    CrossrefPubMedGoogle Scholar
  • 7 Pawashe AB, Golino P, Ambrosio G, Migliaccio F, Ragni M, Pascucci I, Chiariello M, Bach R, Garen A, Konigsberg WK, Ezekowitz MD. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res 1994; 74: 56-63
    CrossrefPubMedGoogle Scholar
  • 8 Wilcox JN, Smith KMWilliams, Schwartz SM, Gordon D. Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization. J Clin Invest 1988; 82: 1134-1143
    CrossrefPubMedGoogle Scholar
  • 9 Østerud B. Cellular interactions in tissue factor expression by blood mono cytes. Blood Coag Fibrinol 1995; 06: S20-S25
    PubMedGoogle Scholar
  • 10 Landers SC, Gupta M, Lewis JC. Ultrastructural localization of tissue factor on monocyte-derived macrophages and macrophage foam cells associated with atherosclerotic lesions. Virchows Archiv 1994; 425: 49-54
    PubMedGoogle Scholar
  • 11 Lewis JC, Bennett-Cain AL, DeMars CS, Doellgast GJ, Grant KW, Jones NL, Gupta M. Procoagulant activity after exposure of monocyte-derived macrophages to minimally oxidized low density lipoprotein. Co-localization of tissue factor antigen and nascent fibrin fibers at the cell surface. Am J Pathol 1995; 147: 1029-1040
    PubMedGoogle Scholar
  • 12 Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Circulation 1985; 71: 699-708
    CrossrefPubMedGoogle Scholar
  • 13 Annex BH, Denning SM, Channon KM, Sketch MH, Stack RS, Morrissey JH, Peters KG. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995; 91: 619-622
    CrossrefPubMedGoogle Scholar
  • 14 Holst J, Lindblad B, Bergqvist D, Nordfang O, Østergaard PB, Petersen JGL, Nielsen G, Hedner U. Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thromosis – a comparison with low molecular weight heparin. Thromb Haemost 1994; 71: 214-219
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D, Wilcox JN. Antithrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis. Arterioscler Thromb 1992; 12: 948-954
    CrossrefPubMedGoogle Scholar
  • 16 Taylor Jr BF, Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett R, Blick K, Edgington TS, Lethal E. Coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 127-134
    PubMedGoogle Scholar
  • 17 Levi M, ten Cate H, Bauer KA, van derPoll, Edginton TS, Buller HR, van DeventerSJH, Hack CE, ten Cate JW, Rosenberg RD. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-120
    CrossrefPubMedGoogle Scholar
  • 18 Warr TA, Vijaya MohanRao, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: Effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75: 1481-1489
    PubMedGoogle Scholar
  • 19 Haskel EJ, Ton SR, Day KC, Palmier MO, Wun TC, Sobel BE, Abend-schein DR. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991; 84: 821-827
    CrossrefPubMedGoogle Scholar
  • 20 Abendschein DR, Meng YY, Torr-Brown S, Sobel BE. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation 1995; 92: 944-949
    CrossrefPubMedGoogle Scholar
  • 21 Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M, Nemerson Y, Taubman MB. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 1993; 91: 2253-2259
    CrossrefPubMedGoogle Scholar
  • 22 Speidel CM, Eisenberg PR, Ruf W, Edgington TS, Abendschein DR. Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits. Circulation 1995; 92: 3323-3330
    CrossrefPubMedGoogle Scholar
  • 23 Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995; 92: 3041-3050
    CrossrefPubMedGoogle Scholar
  • 24 Ragni M, Cirillo P, Pascucci I, Scognamiglio A, D’Andrea D, Eramo N, Ezekowitz MD, Pawashe AB, Chiariello M, Golino P. Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Circulation 1996; 93: 1913-1918
    CrossrefPubMedGoogle Scholar
  • 25 Golino P, Ambrosio G, Pascucci I, Ragni M, Russolillo E, Chiariello M. Experimental carotid stenosis and endothelial injury in the rabbit: an in vivo model to study intravascular platelet aggregation. Thromb Haemost 1992; 67: 302-305
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Folts JD. An in-vivo model of experimental arterial stenosis, intimal damage and periodic thrombosis. Circulation 1991; 83 (Suppl. 04) 3-14
    PubMedGoogle Scholar
  • 27 Tijburg PNM, Ijsseldijk MJW, Sixma JJ, de GrootPG. Quantification of fibrin deposition in flowing blood with peroxidase-labeled fibrinogen. High shear rates induce decreased fibrin deposition and appearance of fibrin monomers. Arterioscl Thromb 1991; 11: 211-220
    CrossrefPubMedGoogle Scholar
  • 28 Tijburg PNM, Ryan J, Stem DM, Wollitzky B, Rimon S, Rimon A, Handley D, Nawroth P, Sixma JJ, de GrootPG. Activation of the coagulation mechanism on tumor necrosis factor-stimulated cultured endothelial cells and their extracellular matrix. The role of flow and factor IX/IXa. J Biol Chem 1991; 266: 12067-12074
    PubMedGoogle Scholar
  • 29 Goldsmith HL, Turitto VT. Rheological aspects of thrombosis and haemostasis: basic principles and applications. Thromb Haemost 1986; 55: 415-435
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Carteaux JP, Gast A, Tschopp TB, Roux S. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. Circulation 1994; 91: 1568-1574
    PubMedGoogle Scholar
  • 31 Giles AR, Tinlin S, Greenwood R. A canine model of hemophilic (Factor VIILC deficiency) bleeding. Blood 1982; 60: 727-730
    PubMedGoogle Scholar
  • 32 Gast A, Tschopp TB, Baumgartner HR. Thrombin plays a key role in late platelet thrombus growth and/or stability. Effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood. Arterioscler Thromb 1994; 14: 1466-1474
    CrossrefPubMedGoogle Scholar
  • 33 Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10: 399-410
    CrossrefPubMedGoogle Scholar
  • 34 Hilpert K, Ackermann J, Banner DW, Gast A, Gubemator K, Hadvàry P, Labler L, Muller K, Schmid G, Tschopp TB, Van de Waterbeemd H. Design and synthesis of potent and highly selective thrombin inhibitors. J Med Chem 1994; 37: 3889-3901
    CrossrefPubMedGoogle Scholar
  • 35 Golino P, Ragni M, Cirillo P, Avvedimento VE, Feliciello A, Esposito N, Scognamiglio A, Trimarco B, Iaccarino G, Condorelli M, Chiariello M, Ambrosio G. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nature Med 1996; 02: 35-40
    CrossrefPubMedGoogle Scholar
  • 36 Giles RA. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987; 58: 1078-1084
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Kozma C, Macklin W, Cummins M, Mauer R. Anatomy, physiology, and biochemistry of the rabbit. in: The Biology of the Laboratory Rabbit. Weisbroth SH, Flatt RE, Kraus AL. eds. Academic Press; New York and London: 1974. pp 50-69
    Google Scholar
  • 38 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors. J Clin Invest 1990; 86: 385-391
    CrossrefPubMedGoogle Scholar
  • 39 Gast A, Tschopp TB, Schmid G, Hilpert K, Ackermann J. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coagul Fibrinolysis 1994; 05: 879-887
    CrossrefPubMedGoogle Scholar
  • 40 Bovill EG, Harker LA, Hirsh J. The physiology and clinical efficacy of the newer antithrombotic agents. 1995; education program – American Society of Hematology, Seattle, Washington. pp 59-66
    PubMedGoogle Scholar
  • 41 Garabedian HD, Gold HK, Leinbach RC, Svizzero TA, Finkelstein DM, Guerrero JL, Collen D. Bleeding time prolongation and bleeding during infusion of recombinant tissue-type plasminogen activator in dogs: potenti ation by aspirin and reversal with aprotinin. J Am Coll Cardiol 1991; 17: 1213-1222
    CrossrefPubMedGoogle Scholar
  • 42 Vaughan DE, Declerck PJ, De MolM, Collen D. Recombinant plasmino gen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits. J Clin Invest 1989; 84: 586-591
    CrossrefPubMedGoogle Scholar
  • 43 Gimple LW, Gold HK, Leinbach MC, Coller BS, Werner W, Yasuda T, Johns JA, Ziskind AA, Finkelstein D, Collen D. Correlation between tem plate bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 1989; 80: 581-588
    CrossrefPubMedGoogle Scholar
  • 44 Vanderschueren S, Collen D. Comparative effects of staphylokinase and alteplase in rabbit bleeding time models. Thromb Haemost 1996; 755: 816-819
    PubMedGoogle Scholar
  • 45 Giles AR, Tinlin S, Brosseau L, Hoogendoom H. In vivo studies of the role of factor VII in hemostasis. Blood 1985; 65: 1197-1200
    PubMedGoogle Scholar
  • 46 Tuddenham EGD, Pemberton S, Cooper DN. Inherited factor VII deficien cy: genetics and molecular pathology. Thromb Haemost 1995; 74: 313-321
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Weiss HJ, Lages B. Evidence for tissue-factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time in wounds. Blood 1988; 71: 629-635
    PubMedGoogle Scholar
  • 48 Fair DS, MacDonald MJ. Cooperative interaction between factor VII and cell surface-expressed tissue factor. J Biol Chem 1987; 262: 11692-1168
    PubMedGoogle Scholar
  • 49 Vandervelden P, Giles AR. A detailed morphological evaluation of the evolution of the haemostatic plug in normal, factor VII and factor VIII deficient dogs. Br J Haemato 1988; 70: 345-355
    CrossrefPubMedGoogle Scholar